Announcements Trials
Browse Landscape

Phase

Phase 4 2Phase 1/2 1

Status

Recruiting 3Active not recruiting 3Completed 2Not yet recruiting 1

Sponsor Class

INDUSTRY 2OTHER 1

Study Type

Interventional 3

Sponsor

Cancer Type

CNS 3Thoracic 1Myeloid 1Dermatologic 1

Conditions

Melanoma 4Thyroid Carcinoma, Anaplastic 3Neoplasms 3Glioma 3Colorectal Neoplasms 2Carcinoma, Non-Small-Cell Lung 2Thyroid Neoplasms 1Spinocerebellar Degenerations 1Solid Tumor 1Skin Neoplasms 1Sexual Dysfunction, Physiological 1Refractory Differentiated Thyroid Gland Carcinoma 1Recurrence 1Rare Malignant Neoplasm 1Oligodendroglioma 1Neurofibromatosis 1 1Neurofibroma, Plexiform 1Neurocytoma 1Neuroblastoma 1Neoplasm Metastasis 1Multiple Myeloma 1Lymphoma, Non-Hodgkin 1Lung Neoplasms 1Locally Advanced Thyroid Gland Carcinoma 1Histiocytosis, Langerhans-Cell 1Hematologic Neoplasms 1Glioblastoma 1Ganglioneuroma 1Ganglioglioma 1Eunuchism 1

Interventions

Magnetic Resonance Spectroscopy 19Temozolomide 16Radiotherapy 10Specimen Handling 7Blood Specimen Collection 7Radiation 6Bevacizumab 5Nivolumab 4Cyclophosphamide 4Biopsy 4vorasidenib 3trametinib 3pembrolizumab 3olaparib 3fludarabine 3dabrafenib 3Watchful Waiting 3Surgical Procedures, Operative 3Magnetic Resonance Imaging 3Drug Therapy 3olutasidenib 2lutetium Lu 177 dotatate 2fluorodopa F 18 2fluciclovine F-18 2entrectinib 2contrast agent BR1 2Restraint, Physical 2Radiosurgery 2Microdialysis 2Flucytosine 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Recruiting × Glioma × dabrafenib × Clear all
NCT03975829 2026-06-02

Pediatric Long-Term Follow-up and Rollover Study

Novartis

Phase 4 Recruiting
165 enrolled
CNSMyeloid

Astrocytoma, Ganglioneuroma, Glioblastoma, Glioma, Histiocytosis, Langerhans-Cell, Neuroblastoma, Neurofibromatosis 1, Oligodendroglioma, Ganglioglioma, Neurocytoma, Neurofibroma, Plexiform

NCT03340506 2026-04-20

Dabrafenib and/or Trametinib Rollover Study

Novartis

Phase 4 Recruiting
100 enrolled
CNSDermatologicThoracic

Carcinoma, Non-Small-Cell Lung, Glioma, Lung Neoplasms, Melanoma

NCT06712875 2025-05-29

MAPK Inhibition Combined With Anti-PD1 Therapy for BRAF-altered Pediatric Gliomas

Ann & Robert H Lurie Children's Hospital of Chicago

Phase 1/2 Recruiting
27 enrolled
CNS

Glioma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡